Pharmacokinetics of Ofloxacin - Measurement of Drug Concentration in Saliva of Patients with Impaired Renal Function

Fujita, Kiyoshi; Matsuoka, Natsumi; Takenaka, Ikumasa; Hiraishi, Koji; Yokota, Takashi; Asahi, Takeshi; Tatara, Katsunori; Yuasa, Makoto; Kaifu, Yasuo; Kawano, Atsuko; Akiyama, Kenji

doi:10.2165/00003495-199500492-00082

Cited by 4 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All included articles were assessed for risk of bias. Baglie et al, 22 Biasini et al, 23 Brown et al, 24 Fujita et al, 25 Goddard et al, 26 and Ohkubo et al 27 were considered at a serious risk of bias (Table 2). This means that the studies have some serious problems with bias for a nonrandomized study.…”

Section: Resultsmentioning

confidence: 99%

“…Fujita et al 25 and Biasini et al 23 were judged at a serious risk of bias because important information, for instance, the sampling or analytical procedure, was scarcely described. Fujita et al 25 did not mention any validation of the analytical method, whereas Biasini et al 23 provided too little information about the analytical procedures to estimate the risk of bias. Goddard et al 26 did not use paired sampling for all time points.…”

Section: Resultsmentioning

confidence: 99%

“…Isoniazid, 24,31,40 moxifloxacin, 34–38 ofloxacin, 21,25,27,41,44–49 and clarithromycin 26,38,50–52 showed varying saliva–plasma and saliva–serum ratios. The same issue applied to rifampicin, although rifampicin showed some low saliva–plasma and saliva–serum ratios that could complicate the detection of the drug in saliva for low-dosage regimes.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

Elsen

Oostenbrink

Heysell

et al. 2018

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

For gatifloxacin and linezolid, salivary therapeutic drug monitoring is likely possible due to a narrow range of saliva-plasma and saliva-serum ratios. For isoniazid, rifampicin, moxifloxacin, ofloxacin, and clarithromycin, salivary therapeutic drug monitoring might be possible; however, a large variability in saliva-plasma and saliva-serum ratios was observed. Unfortunately, salivary therapeutic drug monitoring is probably not possible for doripenem and amoxicillin/clavulanate, as a result of very low salivary drug concentrations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

Elsen

Oostenbrink

Heysell

et al. 2018

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…Koizumi et al (1994) reported a ratio of 1.0 between 2-8 h after administration of a 300 mg dose. Fujita et al (1995) in their studies on patients with renal impairment had reported a ratio of 1:1 for saliva to serum concentrations. However, Warlich et al (1990) have reported a ratio of 0.6 and a close relation of levels in the saliva and serum (r= 0.99), which is consistent with our findings.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of isoniazid with or without ofloxacin

2012

View full text Add to dashboard Cite

Objective of the resent study was to determine the effect of ofloxacin (OXC) on the pharmacokinetics of isoniazid (INH). Five healthy volunteers aged 18 39 years participated in this study after an informed consent. The study was carried out in two phases with an interval of one-week drug wash out period in between phases. In phase one (INH alone), each subject received 300mg of isoniazid (INH) with 350ml of water after an overnight fast. The subjects were made to fast 2 hours post drug. In phase two (INH + OXC), each subject was administered with 300mg of INH in combination with 200mg of OXC observing all the protocol in phase one. The concentration of INH in plasma, saliva and urine of the subjects at predetermined time intervals were measured spectrophotometrically in the two phases over a period of 0 - 48 hours. Various pharmacokinetics parameters were calculated. From the study it is evident that Ofloxacin (OXC) increased the rate and extent of absorption of isoniazid. The absorption half-life (t1/2a) and the maximum concentration and absorption time (Cmax, Tmax) of isoniazid (INH) were increased in the presence of OXC. The urinary excretion of isoniazid was also increased by ofloxacin. The salivary concentration of isoniazid was less than the corresponding plasma drug concentrations, a pattern also found in similar studies. Thus it can be concluded that Ofloxacin increases absorption kinetics and urinary excretion of Isoniazid.DOI: http://dx.doi.org/10.3329/icpj.v1i12.12449 International Current Pharmaceutical Journal 2012, 1(12): 403-409

show abstract

A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans

Kiang

Ensom

2015

Clin Pharmacokinet

View full text Add to dashboard Cite

We conducted a systematic search to describe the current state of knowledge regarding the utility of saliva for clinical pharmacokinetic monitoring (CPM) of antibiotics. Although the majority of identified studies lacked sufficient pharmacokinetic data needed to assign an appropriate suitability classification, most aminoglycosides, fluoroquinolones, macrolides, penicillins/cephalosporins, and tetracyclines are likely not suitable for CPM in saliva. No clear pattern of correlation was observed between physiochemical properties that favor drug distribution into saliva and the likelihood of the antibiotic being classified as suitable for CPM in saliva (and vice versa). Insufficient data were available to determine if pathophysiological conditions affected salivary distribution of antibiotics. Additional confirmatory data are required for drugs (especially in patients) that are deemed likely suitable for CPM in saliva because only a few studies were available and many focused only on healthy subjects. All studies identified had relatively small sample sizes and exhibited large variability. Very few studies reported salivary collection parameters (e.g., salivary flow, pH) that could potentially have some impact on drug distribution into saliva. The available data are heavily weighted on healthy subjects, and insufficient data were available to determine if pathophysiology had effects on saliva drug distribution. Some studies also lacked assay sensitivity for detecting antibiotics in saliva. Overall, this review can be useful to clinicians who desire an overview on the suitability of saliva for conducting CPM of specific antibiotics, or for researchers who wish to fill the identified knowledge gaps to move the science of salivary CPM further.

show abstract

Pharmacokinetics of Ofloxacin - Measurement of Drug Concentration in Saliva of Patients with Impaired Renal Function

Cited by 4 publications

References 1 publication

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring

Pharmacokinetics of isoniazid with or without ofloxacin

A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans

Contact Info

Product

Resources

About